These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7310392)

  • 41. Effects of ibopamine on serum prolactin and growth hormone levels in hyperprolactinemic and acromegalic subjects.
    Ferrari C; Barbieri C; Caldara R; Rampini P; Paracchi A; Boghen M; Rauhe WG
    Clin Pharmacol Ther; 1983 Jul; 34(1):74-8. PubMed ID: 6861440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of ECT in patients with parkinsonism.
    Moellentine C; Rummans T; Ahlskog JE; Harmsen WS; Suman VJ; O'Connor MK; Black JL; Pileggi T
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):187-93. PubMed ID: 9608407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinsonism: improvement by electroconvulsive therapy.
    Levy LA; Savit JM; Hodes M
    Arch Phys Med Rehabil; 1983 Sep; 64(9):432-3. PubMed ID: 6615182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective effects of ECT on hypothalamic-pituitary activity.
    Whalley LJ; Eagles JM; Bowler GM; Bennie JG; Dick HR; McGuire RJ; Fink G
    Psychol Med; 1987 May; 17(2):319-28. PubMed ID: 3037582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides.
    Fall PA; Ekman R; Granérus AK; Thorell LH; Wålinder J
    J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):129-40. PubMed ID: 9620060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
    Papavasiliou PS; Cotzias GC; Rosal VL; Miller ST
    Arch Neurol; 1978 Dec; 35(12):787-91. PubMed ID: 363104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
    Rabey JM; Vardi Y; Ravid R; Ayalon D
    Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adrenergic and dopaminergic control of growth hormone secretion in urethan anesthetized adult male rats.
    Ruch W; Marbach P; Jaton AL; Bucher B; Doepfner W
    Horm Res; 1978; 9(4):208-24. PubMed ID: 669571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of stimulus intensity on prolactin and cortisol release induced by unilateral electroconvulsive therapy.
    Zis AP; Yatham LN; Lam RW; Clark CM; Srisurapanont M; McGarvey K
    Neuropsychopharmacology; 1996 Sep; 15(3):263-70. PubMed ID: 8873109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The effect of a single electroconvulsive shock on pituitary-thyroid-adrenal-gonadal axis function in men with severe depression--preliminary report].
    Motta E; Ostrowska Z; Kazibutowska Z; Paluch M; Płonka J; Gołba A
    Psychiatr Pol; 2005; 39(3):469-79. PubMed ID: 16149757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal growth hormone responsiveness to stimuli in women with active celiac sprue.
    Peracchi M; Molteni N; Cantalamessa L; Bardella MT; Peracchi G; Orsatti A; Faggioli P; Bianchi PA
    Am J Gastroenterol; 1992 May; 87(5):580-3. PubMed ID: 1595643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thyrotropin and prolactin responses to ECT in schizophrenia and depression.
    Papakostas Y; Markianos M; Papadimitriou G; Lykouras L; Stefanis C
    Psychiatry Res; 1991 Apr; 37(1):5-10. PubMed ID: 1862162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Naloxone has no effect on hormonal responses to ECT in man.
    Turner TH; Ur E; Grossman A
    Psychiatry Res; 1987 Nov; 22(3):207-12. PubMed ID: 2829259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modification of the actions of some neuroactive drugs by growth hormone.
    Tang LC; Cotzias GC
    Arch Neurol; 1976 Feb; 33(2):131-4. PubMed ID: 1252146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The correlationship between basal prolactin levels and the suppressive effect of CB-154 or L-DOPA on GH release in acromegalic patients (author's transl)].
    Hara I; Kataoka K; Tomita A; Takanohashi M; Nakane T; Kuwayama A; Kageyama N
    Nihon Naibunpi Gakkai Zasshi; 1979 Jan; 55(1):16-24. PubMed ID: 581754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of thyrotropin-releasing hormone administration on the electroconvulsive therapy induced prolactin responses and seizure time.
    Papakostas Y; Markianos M; Pehlivanidis A; Papadimitriou GN; Zervas IM; Daras M; Stefanis C
    Biol Psychiatry; 1996 Mar; 39(6):444-7. PubMed ID: 8679790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.